Vividion Therapeutics is a biotechnology company focused on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome-wide ligand and target discovery. Headquartered in San Diego, CA, Vividion Therapeutics is a private, biotechnology company founded in 2014 with seed financing from Cardinal Partners as a spin out from the labs of Dr. Benjamin Cravatt, Dr. Phil Baran and Dr. Jin-Quan Yu at TSRI. In 2017, Vividion launched with $50 million in Series A financing from ARCH Venture Partners, Versant Ventures and founding investor Cardinal Partners.